Simulations Plus delivered a modestly profitable Q1 2026, with strong service revenue offsetting a decline in software sales. The company reaffirmed its full-year guidance and emphasized growth opportunities in AI-powered drug development.

Simulations Plus reported a 6% decrease in total revenue to $17.5 million for Q4 2025, with a net loss of $0.7 million and diluted loss per share of $0.03. For the full fiscal year 2025, total revenue increased 13% to $79.2 million, and adjusted diluted EPS was $1.03.

Despite a $77.2M non-cash impairment leading to a GAAP net loss, Simulations Plus posted double-digit revenue growth and improved adjusted EPS, driven by strong software and services performance.

Simulations Plus delivered a strong Q2 2025 with 23% revenue growth year-over-year, driven by robust expansion in software and services. However, GAAP net income declined versus the prior year.

Simulations Plus reported a 31% increase in total revenue for the first quarter of fiscal year 2025, primarily driven by a 41% increase in software revenue. The company's MonolixSuite™ and Quantitative Systems Pharmacology (QSP) business units showed significant growth. However, the services segment faced temporary headwinds due to client-driven data delays.

Simulations Plus reported strong Q4 2024 results, with total revenue increasing by 19% to $18.7 million. The company's software and services segments both contributed to the growth, with software revenue increasing by 6% and services revenue increasing by 39%.

Simulations Plus reported a 14% increase in total revenue to $18.5 million for the third quarter of fiscal year 2024. EPS was $0.15, compared to $0.20 in the same quarter last year. The company maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance.

Simulations Plus reported a 16% increase in total revenue to $18.3 million and EPS of $0.20 for the second quarter of fiscal year 2024. The company maintains its full-year revenue guidance of $66 to $69 million and EPS guidance of $0.66 to $0.68.

Simulations Plus reported a successful start to fiscal year 2024, with a 21% increase in total revenue to $14.5 million and diluted earnings per share of $0.10. The company maintains its full-year revenue and EPS guidance.

Simulations Plus reported a 33% increase in Q4 revenue to $15.6 million, driven by a 59% increase in software revenue and an 8% increase in services revenue. The company's adjusted EPS was $0.18, with a net income of $0.5 million.

Simulations Plus reported a solid third quarter with revenue in line with expectations, driven by strong performance in the software segment and growth in services. The company maintains its full-year revenue and EPS guidance.

Simulations Plus reported a 6% increase in total revenue to $15.8 million for the second quarter of fiscal year 2023. The company maintains its full-year revenue guidance of $59.3 - $62.0 million and EPS guidance of $0.63 - $0.67.

Simulations Plus reported a 4% decrease in total revenue to $12.0 million for Q1 2023. Diluted EPS was $0.06. The company is focusing on corporate development activities, a $50 million share repurchase program, and internal investment.

Simulations Plus reported a strong fourth quarter with a 19% increase in total revenue to $11.7 million. Full-year revenue grew by 16% to $53.9 million, and diluted earnings per share increased by 28% to $0.60.

Simulations Plus reported a 17% increase in total revenue, driven by strong growth in both software (16%) and services (19%). The company's diluted EPS also increased by 11%.

Simulations Plus reported a 13% increase in total revenue, driven by a 25% growth in software revenue. Diluted EPS grew by 40%. The company's Board of Directors announced a quarterly dividend of $0.06 per share.

Simulations Plus reported a strong first quarter with double-digit revenue growth driven by the software business and improving momentum in the services business. The company saw a 22% improvement in net income due to a higher software versus services revenue mix.

Simulations Plus reported a 3% increase in total revenue for Q4 2021, driven by a 14% increase in software revenue, while services revenue declined by 7%. The company's software business demonstrated strong performance, while the services business is building backlog.

Simulations Plus reported a 4% increase in total revenue to $12.8 million for the third quarter of fiscal 2021. Software revenue increased by 21%, but overall growth was moderated by delays in the services business. The company expects full-year revenue growth of 5 to 10%.

Simulations Plus reported a strong second quarter with a 27% increase in revenue, driven by global sales of software and services. The company also successfully completed its first sponsored conference and released new versions of GastroPlus® and Monolix Suite™.

Simulations Plus reported strong first-quarter results with a 14% year-over-year revenue increase to $10.7 million and increased profitability, driven by strategic investments and the acquisition of Lixoft.

Simulations Plus reported an 18.9% increase in fourth quarter revenue, reaching $9.5 million. The company's diluted EPS for the quarter was $0.11.